■人类表皮生长因子受体2(HER2)的过度表达与发生远处转移的风险升高密切相关,特别是脑转移,在乳腺癌(BC)病例中。RC48(也称为Diitamabvedotin),代表一种有前途的抗体-药物偶联物(ADC),它包含三个明确定义的成分:针对突出肿瘤靶标HER2的hertuzumab,单甲基奥瑞他汀E(MMAE)和可裂解的接头。临床前研究已证明其在具有HER2阳性或HER2低表达的BC患者来源的异种移植模型中具有强大的抗肿瘤活性。此外,贝伐单抗等抗血管生成药物通过抑制病理性新生血管形成对晚期BC具有潜在疗效.
■这里,我们将分享我们对一名49岁女性的治疗经验,该女性最初被诊断为以激素受体(HR)阴性和HER2阳性为特征的IV期乳腺癌.这个复杂的病例涉及脑和肝转移,患者对各种HER2靶向治疗方案表现出耐药性.最后,患者接受RC48加贝伐单抗作为晚期四线治疗,耐受性良好,没有观察到毒性。随后的放射学评估显示脑转移性病变明显消退,根据RECIST1.1系统分类为具有部分响应。无进展生存期(PFS)为7个月。
■本研究强调了RC48联合全身治疗的疗效,显示脑转移性乳腺癌(BMBC)患者的影像学指标和临床症状学均有显着增强。更具体地说,序贯应用ADC联合抗血管生成药物为推进转移性BC的治疗前景提供了新的途径.
UNASSIGNED: The overexpression of human epidermal growth factor receptor 2 (HER2) is strongly correlated with an elevated risk of developing distant metastases, particularly brain metastases, in breast cancer (BC) cases. RC48 (also known as Disitamab vedotin), represents a promising antibody-drug conjugate (ADC), that comprises three well-defined components: hertuzumab against the prominent tumor target-HER2, monomethyl auristatin E (MMAE) and a cleavable linker. Preclinical studies have demonstrated its robust antitumor activity in BC patient-derived xenograft models with HER2-positive or HER2-low expression. Additionally, antiangiogenic drugs like bevacizumab have shown potential efficacy on advanced BC via inhibiting pathological neovascularizationits.
UNASSIGNED: Here, we will share our experience in treating a 49-year-old woman initially diagnosed with stage IV breast cancer characterized by hormone receptor (HR)-negativity and HER2-positivity. This complex
case entailed brain and liver metastases, and the patient exhibited resistance to various HER2-targeted treatment regimens. Finally, the patient received RC48 plus bevacizumab as the advanced forth-line treatment, which was well tolerated with no observed toxicities. Subsequent radiological assessments revealed remarkable regression in the brain metastatic lesions, classified as having partial response based on the RECIST 1.1 system. The period of progression-free survival (PFS) was 7 months.
UNASSIGNED: The present study underscores the efficacy of systemic treatment with RC48 in conjunction, showcasing substantial enhancement in both radiographic indicators and clinical symptomatology among patients with brain metastatic breast cancer (BMBC). More specifically, the sequential application of ADCs in combination with antiangiogenics presents a novel avenue for advancing the treatment landscape of metastatic BC.